- Home
- KLTO vs SEPN Comparison
KLTO vs SEPN Comparison
Compare KLTO & SEPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLTO
- SEPN
- Stock Information
- Founded
- KLTO 2019
- SEPN 2022
- Country
- KLTO United States
- SEPN United States
- Employees
- KLTO N/A
- SEPN N/A
- Industry
- KLTO
- SEPN
- Sector
- KLTO
- SEPN
- Exchange
- KLTO NYSE
- SEPN NYSE
- Market Cap
- KLTO 5.9M
- SEPN 453.2M
- IPO Year
- KLTO N/A
- SEPN 2024
- Fundamental
- Price
- KLTO $1.29
- SEPN $12.61
- Analyst Decision
- KLTO
- SEPN Strong Buy
- Analyst Count
- KLTO 0
- SEPN 5
- Target Price
- KLTO N/A
- SEPN $26.75
- AVG Volume (30 Days)
- KLTO 14.6M
- SEPN 398.8K
- Earning Date
- KLTO 08-15-2025
- SEPN 08-15-2025
- Dividend Yield
- KLTO N/A
- SEPN N/A
- EPS Growth
- KLTO N/A
- SEPN N/A
- EPS
- KLTO N/A
- SEPN N/A
- Revenue
- KLTO N/A
- SEPN $977,000.00
- Revenue This Year
- KLTO N/A
- SEPN $3,429.67
- Revenue Next Year
- KLTO N/A
- SEPN N/A
- P/E Ratio
- KLTO N/A
- SEPN N/A
- Revenue Growth
- KLTO N/A
- SEPN 108.76
- 52 Week Low
- KLTO $0.11
- SEPN $4.17
- 52 Week High
- KLTO $3.91
- SEPN $28.99
- Technical
- Relative Strength Index (RSI)
- KLTO N/A
- SEPN N/A
- Support Level
- KLTO N/A
- SEPN N/A
- Resistance Level
- KLTO N/A
- SEPN N/A
- Average True Range (ATR)
- KLTO 0.00
- SEPN 0.00
- MACD
- KLTO 0.00
- SEPN 0.00
- Stochastic Oscillator
- KLTO 0.00
- SEPN 0.00
About KLTO KLOTHO NEUROSCIENCES INC
Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.
About SEPN SEPTERNA INC
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.